InKine Appoints John M. Cullen, Ph.D., J.D. to Senior Vice President and General Counsel.

BLUE BELL, Pa. -- InKine Pharmaceutical Company, Inc. (Nasdaq: INKP) today announced the appointment of John M. Cullen, Ph.D, J.D. to the newly created position of Senior Vice President and General Counsel, reporting to Leonard S. Jacob, M.D., Ph.D., Chairman and Chief Executive Officer of InKine. Dr. Cullen spent over 20 years at SmithKline Beecham where he was Vice President, Associate General Counsel and Assistant Secretary and provided all legal services to the North American Business Operations. In 1994 he became Chief Operating Officer for IBAH (presently Omnicare) a contract research organization. For the last 7 years he has independently provided legal and regulatory advice to pharmaceutical and biotechnology companies. Dr. Cullen also serves as Adjunct Professor of Food and Drug Law at Temple University. He received his Ph.D. in Biochemistry from Seton Hall University, was a Post-Doctoral Fellow in Immunophysiology at Stanford University and received his J.D. from Temple University.

"John is a seasoned professional with substantial international, corporate, regulatory and business development experience in the pharmaceutical industry," said Dr. Jacob. "We are delighted to have John join InKine as the newest member of InKine's senior executive team," added Dr. Jacob.

About InKine Pharmaceutical

InKine Pharmaceutical Company, Inc. is a publicly traded specialty pharmaceutical company focused on developing and commercializing pharmaceutical products for the diagnosis and treatment of gastrointestinal disorders. The Company's development strategy is to acquire late-stage drug candidates with short time lines to commercialization. The Company's franchise product, Visicol(R) is the only tablet purgative preparation indicated for bowel cleansing prior to colonoscopy. InKine's second product, IB-Stat(R), is an oral hyoscyamine spray for the treatment of a variety of indications. The Company is also promoting VSL#3(R), a probiotic that is effective in treating certain gastrointestinal disorders. Additionally, the Company is developing INKP-102, an advanced generation purgative, which recently completed Phase III clinical trials for bowel cleansing prior to colonoscopy and studying Visicol(R) for use as a laxative in treating patients with constipation. For further information, please visit InKine on its web site http://www.inkine.com.

In addition to historical facts or statement of current condition, this press release and other statements made from time to time by representatives of the Company contain or may contain forward-looking statements. Forward-looking statements provide InKine's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings projections, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. InKine's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties such as those set forth in its reports on Form 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, InKine does not intend (and it is not obligated) to update publicly any forward-looking statements. This discussion is permitted by the Private Securities Litigation Reform Act of 1995.